Profile data is unavailable for this security.
About the company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
- Revenue in DKK (TTM)134.61bn
- Net income in DKK46.18bn
- Incorporated1931
- Employees46.98k
- LocationNovo Nordisk A/SNovo Alle 1BAGSVAERD 2880DenmarkDNK
- Phone+45 44448888
- Fax+45 44436633
- Websitehttps://www.novonordisk.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 28.60bn | 3.70bn | 328.01bn | 14.41k | 88.95 | 6.26 | 45.93 | 11.47 | 6.88 | 9.52 | 53.25 | 97.83 | 0.2732 | -- | -- | 240,386.90 | 3.55 | 5.12 | 4.32 | 6.35 | 41.95 | 38.95 | 13.00 | 13.11 | -- | 26.49 | 0.3319 | 33.19 | 7.15 | 3.46 | 12.83 | 21.39 | 29.81 | 5.31 |
| GlaxoSmithKline plc | 295.41bn | 38.23bn | 720.17bn | 94.07k | 18.92 | 5.27 | 11.54 | 2.44 | 0.8536 | 0.8536 | 6.60 | 3.07 | 0.4176 | 1.69 | 4.29 | 354,283.20 | 6.27 | 6.21 | 9.78 | 10.38 | 67.85 | 68.84 | 15.02 | 12.69 | 0.5358 | 10.26 | 0.5407 | 113.09 | 1.02 | 7.35 | 23.77 | -7.35 | 3.33 | 0.00 |
| Sanofi SA | 286.54bn | 45.96bn | 832.54bn | 99.41k | 18.00 | -- | 14.42 | 2.91 | 4.92 | 4.92 | 30.71 | -- | -- | -- | -- | 387,237.00 | -- | 4.98 | -- | 5.97 | 68.26 | 68.13 | 16.12 | 14.73 | -- | 29.35 | -- | 69.80 | -0.6962 | 1.40 | 323.60 | 22.79 | -5.28 | 1.78 |
| Novo Nordisk A/S | 134.61bn | 46.18bn | 1.08tn | 46.98k | 30.46 | 20.93 | 20.96 | 8.02 | 19.99 | 19.99 | 58.24 | 29.10 | 0.8573 | 1.25 | 4.97 | 3,009,749.00 | 29.41 | 35.30 | 59.69 | 67.18 | 82.89 | 84.10 | 34.31 | 33.51 | 0.8187 | -- | 0.1722 | 50.32 | 4.04 | 3.30 | 8.18 | 3.87 | 28.08 | 7.29 |
| AstraZeneca plc | 215.72bn | 9.67bn | 1.15tn | 76.10k | 88.95 | 4.39 | 26.72 | 5.32 | 0.9397 | 0.9397 | 17.87 | 19.03 | 0.3831 | 1.33 | 4.71 | 319,777.00 | 1.71 | 3.88 | 2.31 | 5.46 | 71.20 | 80.97 | 4.47 | 10.19 | 0.6835 | 2.41 | 0.4443 | 141.03 | 9.16 | 1.50 | 139.40 | 2.50 | -1.34 | 0.2156 |
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2020 | 43.50m | 2.45% |
| The Vanguard Group, Inc.as of 06 Jan 2022 | 42.57m | 2.40% |
| BlackRock Fund Advisorsas of 06 Jan 2022 | 27.57m | 1.56% |
| Alecta Pension Insurance Mutualas of 31 Dec 2019 | 27.09m | 1.53% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2021 | 21.70m | 1.22% |
| Fundsmith LLPas of 30 Jun 2021 | 20.53m | 1.16% |
| BlackRock Investment Management (UK) Ltd.as of 06 Jan 2022 | 20.19m | 1.14% |
| Handelsbanken Fonder ABas of 31 Dec 2021 | 12.29m | 0.69% |
| BlackRock Advisors (UK) Ltd.as of 06 Jan 2022 | 11.98m | 0.68% |
| Allianz Global Investors GmbHas of 20 Jan 2022 | 10.99m | 0.62% |
